Every Form 4 that Eikon Therapeutics, Inc. (EIKN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EIKN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EIKN filings page.
Eikon Therapeutics, Inc. (EIKN) received a Form 4 filing from an investor group associated with The Column Group reporting an open-market purchase of 89,200 shares of Common Stock on September 3, 2026 at a weighted average price of $11.5588 per share. The purchased shares are directly held by Peter Svennilson, while affiliated Column Group funds report indirect holdings of 4,312,139; 148,840; and 1,319,164 shares, and the reporting persons may be deemed to share voting and investment power but each disclaims beneficial ownership beyond their pecuniary interest.
Eikon Therapeutics, Inc. reported that Chief Operating Officer Michael A. Klobuchar received a grant of stock options for 87,157 shares at an exercise price of $0.00 per share. The award vests in equal monthly installments over 48 months, subject to his continued service.
Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics, Inc. reported that director Robert Luther Huffines received a grant of stock options covering 25,873 shares of the company’s stock. These options were awarded as a form of compensation and will vest in equal monthly installments over 48 months, as long as he continues in service during that period.
FRAZIER KENNETH C reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director Kenneth C. Frazier reported a new stock option grant covering 25,873 shares of Eikon Therapeutics common stock on March 2, 2026. The option vests in equal monthly installments over 48 months, conditioned on his continued service with the company.
PERLMUTTER ROGER M reported acquisition or exercise transactions in this Form 4 filing.
Eikon Therapeutics director and officer Roger M. Perlmutter received a grant of stock options covering 268,176 shares of the company’s stock. The options were awarded at no cash cost on the grant date. According to the vesting terms, 1/48 of the underlying shares vest monthly over 48 months, contingent on his continued service.
Eikon Therapeutics, Inc. reported that executive Benjamin Bruno Thorner received a grant of stock options covering 67,044 shares of the company’s stock. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.
According to the vesting terms, one forty-eighth of the option shares will vest on each monthly anniversary of the vesting start date over 48 months, as long as Thorner continues to provide service to the company. This structure ties the award to multi-year retention and ongoing employment.
Eikon Therapeutics Chief Medical Officer Roy D. Baynes reported an option grant giving him rights to acquire 134,088 shares of company stock at an exercise price of $0.00 per share. The option vests in equal monthly installments over 48 months, conditioned on his continued service.
Eikon Therapeutics Chief Financial Officer receives new stock option grant. CFO Alfred Lloyd Bowie Jr. was granted stock options for 67,044 shares of Eikon Therapeutics, Inc. common stock on March 2, 2026, at an exercise price of $0.00 per share, recorded as a grant or award acquisition.
The option vests over four years: 1/48th of the underlying shares vest on each monthly anniversary of the vesting start date for 48 months, provided he continues in service through each vesting date. Following this grant, he directly holds options covering 67,044 shares.
Eikon Therapeutics, Inc. insider Roger M. Perlmutter, the company’s Chief Executive Officer and Director, indirectly acquired 284,857 shares of common stock on February 6, 2026 through derivative conversions tied to the company’s initial public offering.
Series A-1 Preferred Stock representing 1,268,891 shares and Series D Preferred Stock representing 855,512 shares each converted into common stock immediately prior to the IPO closing on a 1-for-7.4578 basis. The resulting common shares are held indirectly for Perlmutter’s benefit through Perlmutter Consulting, Inc., in which he had the sole pecuniary interest.
Entities affiliated with The Column Group reported sizable ownership changes in Eikon Therapeutics, Inc. (EIKN) tied to the company’s initial public offering. On February 6, 2026, multiple funds converted preferred stock into common and also bought additional shares.
The Column Group IV, LP, IV-A, LP and Opportunity III, LP converted Series A, A-1, C-1 and D preferred shares into common stock at an approximate 0.1340878-to-1 ratio and now hold indirect positions including 4,312,139, 148,840 and 1,319,164 common shares, respectively. On the same date, these entities also made open-market purchases of 1,437,323, 49,556 and 630,881 common shares at $18 per share. The filing states that the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Foresite Capital Management IV, LLC reported multiple insider transaction types in a Form 4 filing for EIKN. The filing lists transactions totaling 34,239,351 shares at a weighted average price of $18.00 per share. Following the reported transactions, holdings were 1,943,682 shares.
Eikon Therapeutics director Kenneth C. Frazier bought 111,111 shares of the company’s common stock in an open-market transaction. The purchase took place on February 4, 2026 at a price of $18 per share, and he now directly holds 111,111 shares.
Lux-affiliated investment funds associated with Eikon Therapeutics director and 10% owner Josh Wolfe reported significant share activity around the company’s IPO. On February 4, 2026, Lux Co-Invest Opportunities II and Lux Total Opportunities each bought 138,888 Eikon common shares in open-market transactions at $18 per share, held indirectly through their general partners.
On February 6, 2026, multiple series of Lux-held preferred stock automatically converted into Eikon common stock immediately prior to the IPO at a 1-for-7.4578 conversion rate. This resulted in indirect common stock positions including 2,387,705 shares held for Lux Ventures V, 1,290,428 shares held for a Lux Co-Invest vehicle, and 2,294,653 shares held for a Lux Total Opportunities fund. Voting and dispositive power is exercised by Lux general partner entities; Wolfe and Peter Hebert may be deemed beneficial owners through those entities, while each disclaims beneficial ownership beyond their pecuniary interest.
Eikon Therapeutics, Inc. reported insider transactions by Lux-affiliated investment entities related to its IPO. On February 4, 2026, Lux Co-Invest Opportunities II, L.P. and Lux Total Opportunities, L.P. each indirectly bought 138,888 shares of common stock at $18 per share in open-market purchases.
On February 6, 2026, several Lux funds indirectly acquired common stock through conversions of preferred stock, including 10,000,000 shares of Series A Preferred Stock and multiple series of A-1, B, B-1, C, C-1 and D Preferred Stock. These preferred shares converted into common stock immediately prior to the closing of Eikon’s initial public offering on a 1-for-7.4578 basis. The Lux entities report indirect beneficial ownership, and the managing members, including director Josh Wolfe and Peter Hebert, disclaim beneficial ownership except to the extent of their pecuniary interests.